NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
June 07, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Reports First Quarter 2024 Financial Results
May 22, 2024 08:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 21, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida
May 16, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., May 16, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
May 15, 2024 16:30 ET
|
NeurAxis, Inc.
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces New Medical Policy Coverage in North Dakota
April 23, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
April 09, 2024 16:05 ET
|
NeurAxis, Inc.
CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
April 01, 2024 16:15 ET
|
NeurAxis, Inc.
CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
March 27, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...